AHA Cardiovascular Genome Phenome Study (CVGPS)

 
American Heart Association Cardiovascular Genome Phenome Study (CVGPS) Funding Announcement

The Cardiovascular Genome Phenome Study (CVGPS) is a collaborative effort, spearheaded by the American Heart Association (AHA), to accelerate the future of cardiovascular medicine. CVGPS combines the power of long-term population studies with the precision of molecular analysis to unravel key distinctions between and within subgroups of patients. The discoveries it generates will point the way toward better-targeted, safer, and more effective treatments, based on a deeper understanding of patients’ characteristics, including e.g. risk profiles and therapeutic needs.

The CVGPS is a collaboration among AHA, Boston University (BU) and the University of Mississippi Medical Center (UMMC), the academic coordinating center homes, respectively, of the Framingham Heart Study (FHS) and the Jackson Heart Study (JHS). The Jackson Heart Study also involves Jackson State University (JSU) and Tougaloo College (TC) as partner institutions.

Through the rich diversity of constituent participant/patient populations, CVGPS research will bring inter-individual and patient-to-patient differences into ever sharper focus for common diseases such as atherosclerosis and hypertension.

To accomplish the promise of the CVGPS, AHA is offering two funding opportunities to investigators:
  • CVGPS Pathway Grants 
  • CVGPS Grand Challenge Awards – funded at $500K for 4 years for a total of $2MM
For more information about the desired characteristics, requirements for the application, letter of application and peer review criteria view the full Request for Applications (PDF).

CVGPS Frequently Asked Questions    

Key Dates
Pathway Letter of Application Due       June 3